News about Drug Discovery & Development

Mercy Joins REACH Study to Evaluate GRAIL Galleri Test in Medicare Population

The three year clinical study will assess real-world impact of multi-cancer early detection testing among up to 50,000 Medicare beneficiaries.

Drug Discovery & Development | 09/01/2026 | By News Bureau |  240

Newron Strengthens Evenamide IP Portfolio with New European Patent Approval

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on developing innovative therapies for disorders of the central and peripheral nervous system, announced that the European Patent Office (EPO) has granted an additional patent covering its lead drug candidate, evenamide.

Drug Discovery & Development | 08/01/2026 | By Darshana |  207

Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease

The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.

Drug Discovery & Development | 08/01/2026 | By News Bureau |  253

Inimmune Begins Phase 2 Trial of INI-2004 for Allergic Rhinitis

The randomised, placebo-controlled allergen chamber study will evaluate the safety and efficacy of Inimmune’s immunotherapy candidate INI-2004 in patients exposed to controlled ragweed allergens.

Drug Discovery & Development | 08/01/2026 | By News Bureau |  286

Merck Completes Acquisition of Cidara Therapeutics to Strengthen Influenza Pipeline

Merck, known as MSD outside the United States and Canada, has announced the successful completion of its cash tender offer, through a subsidiary, to acquire Cidara Therapeutics, Inc.

Drug Discovery & Development | 07/01/2026 | By Darshana |  319

Prokaryotics, Basilea Partner to Develop First-in-Class Broad-Spectrum Antifungal

Partnership between Prokaryotics and Basilea will develop broad-spectrum antifungal treatment that targets life-threatening invasive fungal infections.

Drug Discovery & Development | 07/01/2026 | By News Bureau |  178

Bayer Secures Breakthrough Status for Sevabertinib in HER2 NSCLC

US FDA and China’s CDE granted the designation for sevabertinib as a potential first-line therapy in advanced HER2-mutant non-small cell lung cancer.

Drug Discovery & Development | 07/01/2026 | By News Bureau |  390

China Approves Azstarys for ADHD Treatment

ArkBio secures NMPA nod for once-daily ADHD treatment in China.

Drug Discovery & Development | 06/01/2026 | By News Bureau |  541

Semaglutide Patent Expiry to Open Over USD 600 Million Opportunity for Generic Drugmakers

Industry estimates suggest that around 10 to 15 domestic and global drugmakers are likely to compete for this opportunity. In India, the introduction of generic semaglutide formulations, expected during the 2026–27 financial year, could generate incremental revenues of approximately USD 12–24 million within the branded formulations market.

Drug Discovery & Development | 06/01/2026 | By Darshana |  357

FDA Clears BrainSpace's Intellidrop for Automated, Closed-Loop Brain Fluid Management

BrainSpace, a medical technology company developing automated solutions for neurological injury, disease and degeneration, has received US Food and Drug Administration (FDA) 510(k) clearance for Intellidrop, its automated brain fluid management system.

Drug Discovery & Development | 05/01/2026 | By Darshana |  505